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Background: Although complex multivitamin products are widely used as dietary supplements to maintain health
or as special medical food in certain diseases, the effects of these products were not investigated in hyperlipidemia
which is a major risk factor for cardiovascular diseases. Therefore, here we investigated if a preparation developed
for human use containing different vitamins, minerals and trace elements enriched with phytosterol (VMTP) affects
the severity of experimental hyperlipidemia as well as myocardial ischemia/reperfusion injury.
Methods: Male Wistar rats were fed a normal or cholesterol-enriched (2% cholesterol + 0.25% cholate) diet for
12 weeks to induce hyperlipidemia. From week 8, rats in both groups were fed with a VMTP preparation or placebo
for 4 weeks. Serum triglyceride and cholesterol levels were measured at week 0, 8 and 12. At week 12, hearts were
isolated, perfused according to Langendorff and subjected to a 30-min coronary occlusion followed by 120 min
reperfusion to measure infarct size.
Results: At week 8, cholesterol-fed rats showed significantly higher serum cholesterol level as compared to normal
animals, however, serum triglyceride level did not change. VMTP treatment significantly decreased serum
cholesterol level in the hyperlipidemic group by week 12 without affecting triglyceride levels. However, VMTP did
not show beneficial effect on infarct size. The inflammatory marker hs-CRP and the antioxidant uric acid were also
not significantly different.
Conclusions: This is the first demonstration that treatment of hyperlipidemic subjects with a VMTP preparation
reduces serum cholesterol, the major risk factor for cardiovascular disease; however, it does not provide
cardioprotection.
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Oxidative stressBackground
Large clinical studies showed that a significant popula-
tion of adults is affected by hyperlipidaemia in the
developed countries [1]. In the USA, approximately 100
million people (44.4%) suffered from hypercholesterolemia
(>200 mg/dL) in 2008 [2]. It is well known, that hyperlip-
idemia, especially hypercholesterolemia is a major risk* Correspondence: peter.ferdinandy@pharmahungary.com
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reproduction in any medium, provided the orfactor in the development of atherosclerosis and subse-
quent ischemic heart disease [3] which is a leading cause
of death in industrialized countries [4]. Moreover, several
experimental studies have demonstrated that in addition
to its well-known pro-atherogenic effect in the vascula-
ture, hyperlipidemia may directly affect the heart causing
contractile dysfunction [5,6] and attenuated responses
to cardioprotective interventions [7-10].
It has been shown in large clinical trials that
antihyperlipidemic agents e.g. statins [11], fibrates [12],
and niacin [13] could reduce the incidence of cardiovas-
cular events in hypercholesterolemic patients [11].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Ingredients of the VMTP preparation
Active ingredients Amount of ingredient/
1 g product
Daily dose*
Phytosterol 377.4 mg 39.62 mg/kg/day
Coenzim Q10 5.66 mg 0.59 mg/kg/day
Vitamin D3 1.89 μg (75.6 IU) 0.20 μg/kg/day
(8 IU/kg/day)
Vitamin B1 (Thiamine) 0.42 mg 0.04 mg/kg/day
Vitamin B2 (Riboflavin) 0.53 mg 0.06 mg/kg/day
Vitamin B3 (Nicotinic acid) 6.04 mg 0.63 mg/kg/day
Vitamin B6 (Pyridoxine) 0.53 mg 0.06 mg/kg/day
Vitamin B12
(Cyanocobalamine)
0.94 μg 0.10 μg/kg/day
Biotin 18.87 μg 1.98 μg/kg/day
Pantothenic acid 2.26 mg 0.24 mg/kg/day
Folic acid 75.47 μg 7.92 μg /kg/day
Iron 2.64 mg 0.28 mg/kg/day
Manganese 0.38 mg 0.04 mg/kg/day
Copper 0.19 mg 0.02 mg/kg/day
Selenium 6.92 mg 0.73 mg/kg/day
Zinc 1.89 mg 0.20 mg/kg/day
Iodine 28.30 μg 2.97 μg/kg/day
* To conform to the human daily dose of the preparation, rat daily dose was
adjusted according to the ratio of human and rat body surface areas.
Csont et al. Lipids in Health and Disease 2013, 12:138 Page 2 of 8
http://www.lipidworld.com/content/12/1/138Therefore, development of anti-hyperlipidemic stra-
tegies is a crucial point in reducing the risk of coronary
heart disease.
Regular consumption of multivitamin and multimineral
supplements is common in developed countries [14] to
maintain general health. In the United States, more than
half of the adult population use dietary supplements [15]
primarily in the form of multivitamins with or without
minerals [16]. In 1998 a study reported that in Germany
18% of men and 25% of women were regular users of mul-
tivitamins among 18–79 years old adults [17]. Moreover,
sales data show increasing consumption of these products
both in the USA and Europe. The effect of these complex
multivitamin preparations on hyperlipidemia and its con-
sequences is, however, not well understood.
Not only total energy intake and macronutrients inclu-
ding carbohydrates, protein and fat, but also micronutrients
including vitamins, minerals and trace elements may affect
the severity of hyperlipidaemia. A few clinical and experi-
mental studies have shown that some individual vitamins
and vitamin-like substances e.g. coenzyme Q10 [18], B3
[19], and folate [20,21], minerals e.g. iron [22] and copper
[23], and trace elements e.g. selenium [24] beneficially affect
hyperlipidaemia and its complications. In these studies,
effects of individual vitamins, minerals and trace elements
or combination of two or three components were investi-
gated on hyperlipidemia. Interestingly, additional food
supplements prepared from plants including phytosterols
appeared on the market as functional food ingredients.
However, results of large clinical studies on the lipid-
lowering effects of plant sterols and stanols are controver-
sial [25,26], and it is not known if phytosterols may provide
additional benefit in protection of the ischemic heart.
Dietary supplements containing multivitamins, mi-
nerals and trace elements enriched with phytosterol now
are available on the market. Surprisingly, there is only
very limited literature data available on the effects of
such preparations developed for human use on hyperli-
pidemia and its consequences [27].
Therefore, here we aimed to investigate if a commer-
cial VMTP preparation containing 17 different vitamins,
coenzyme Q10, minerals, trace elements and phytosterol
affects the progression of hyperlipidemia and the seve-
rity of myocardial ischemia/reperfusion injury in a diet-
induced experimental model of hyperlipidemia in rats.
Methods
This investigation conforms to the National Institutes of
Health Guide for the Care and Use of Laboratory Ani-
mals (NIH Pub. No. 85–23, Revised 1996) and was ap-
proved by the Animal Research Ethics Committee of the
University of Szeged.
Six weeks old male Wistar rats (170–200 g initial body
weight) were used in the study. Animals were housed inpairs in individually ventilated cages (Sealsafe IVC sys-
tem, Italy) and were maintained in a temperature-
controlled room with a 12-h:12-h light/dark cycles
throughout the study. Standard rat chow and tap water
were supplied ad libitum.
Preparation of vitamins, minerals, trace elements and
phytosterol (VMTP)
The VMTP preparation (“Actival Szterin film-coated tablet”,
Béres Pharmaceuticals, Budapest, Hungary; for content see
Table 1 and Additional file 1: Table S1) investigated in the
present study is a commercially available food supplement
in several countries in Europe. The individual compo-
nents and their daily doses of the VMTP preparation
were selected by the manufacturer on the basis of their
individual preclinical and clinical efficacy and safety data
available in the literature taking into consideration the
Nutritive Reference Values [28].
Experimental protocol
Male Wistar rats were fed a normal or a 2% cholesterol
plus 0.25% cholic acid-enriched diet for 12 weeks to in-
duce experimental hyperlipidemia (Figure 1). At week 0
and 8, fasting serum cholesterol as well as triglyceride
measurements were performed in order to verify the
development of hyperlipidemia (Figure 1). From week
8, both normolipidemic and hyperlipidemic rats were
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Figure 1 Experimental protocol. Male Wistar rats were fed with normal or 2% cholesterol and 0.25% cholic acid enriched diet to induce
experimental hyperlipidemia. At week 8, fasting blood cholesterol and triglyceride measurement were performed in order to verify the
development of hyperlipidemia. Both normolipidemic and hyperlipidemic rats were then fed with placebo or a mixture of vitamins, micro and
trace elements (VMTP) supplemented with phytosterol for 4 weeks. At week 12, fasting blood cholesterol and triglyceride measurement were
performed to monitor the effect of VMTP supplemented with phytosterol on hyperlipidemia. Hearts were then isolated, perfused according to
Langendorff and subjected to a 30-min coronary occlusion followed by 120 min reperfusion to measure infarct size.
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cebo (57.5 mg/kg/day) for 4 weeks (Figure 1). To con-
form to the human daily dose of the preparation, rat
daily dose was adjusted according to the ratio of human
and rat body surface areas. Then fasting serum choles-
terol and triglyceride measurements were performed atSe
ru
m
 tr
ig
lyc
er
id
e
 (m
mo
l/L
)
0
1
2
3
4
B) week 0
A)
Se
ru
m
 c
ho
le
st
er
o
l (m
mo
l/L
)
0
1
2
3
4 week 0
Norm Chol
Norm Chol
Figure 2 Effect of 2% cholesterol plus 0.25% cholic acid-enriched die
level at week 0 (Panel A) and week 8 (Panel C) as well as serum triglyceri
± SEM, *p < 0.05 normal vs. cholesterol-enriched diet; n = 22 in each groupweek 12 to monitor the effect of multivitamin treatment
on hyperlipidemia (Figure 1). At week 12, rats were
anaesthetized using diethyl ether. Hearts were isolated
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Figure 3 Effect of the VMTP preparation on serum cholesterol
and triglyceride levels. Serum cholesterol level at week 12
(Panel A) and serum triglyceride level at week 12 (Panel B). Values
are means ± SEM, *p < 0.05 normal vs. cholesterol-enriched diet;
# p < 0.05 placebo vs. VMTP treatment, n = 11 in each group.
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coronary artery was reoccluded and the area at risk
and the infarcted area were delineated using an Evans
blue/triphenyltetrazolium chloride double staining method
[30,31] (Figure 1).Measurement of serum cholesterol and triglyceride levels
To monitor the effect of 2% cholesterol plus 0.25% cho-
lic acid-enriched diet as well as VMTP treatment on
serum lipid levels, serum cholesterol and triglyceride
levels were measured at week 0, 8 and 12 using a test kit
supplied by Diagnosticum Zrt. (Budapest, Hungary) as
described previously [6,32].
Ex vivo cardiac perfusions and infarct size determination
At week 12, rats were anesthetized and hearts were iso-
lated and perfused at 37°C according to Langendorff
with oxygenated Krebs-Henseleit buffer as previously
described [31,33,34]. Hearts were subjected to 45 minutes
of aerobic perfusion followed by test ischemia-
reperfusion induced by a 30-min occlusion of the left de-
scending coronary artery. A 3–0 silk suture was placed
around the origin of the left descending coronary artery
and passed through a plastic tube to form a snare. After
stabilization of the heart, coronary occlusion was in-
duced by pulling the ends of the suture taut and
clamping the snare onto the epicardial surface. Reperfu-
sion was achieved by releasing the snare as previously
described [31,34] (Figure 1). At the end of the 2-h reper-
fusion protocol, the coronary artery was reoccluded and
5 ml of 0.1% Evans blue dye (Merck, Germany) was
injected into the aorta to delineate the area-at-risk zone.
Stained hearts were weighed, frozen, sliced, and incu-
bated at 37°C in 1% triphenyl-tetrazolium chloride
(Sigma Aldrich, Germany) to delineate infarcted tissue.
Slices were then fixed and quantified by planimetry
using Infarctsize 2.5 software (Pharmahungary, Szeged,
Hungary) [32]. Infarct size was expressed as a percentage
of the area-at-risk zone [30]. The area at risk was calcu-
lated as a percentage of total ventricular area [30].
Measurement of plasma hs-CRP and uric acid levels
Plasma hs-CRP level was measured as a systemic
marker of inflammation at week 12 by a commercially
available immunturbidimetric kit from Roche Diagnostics
(Mannheim, Germany) according to the instructions of
the manufacturer. The functional sensitivity of hs-CRP
assay was 0.11 mg/L and the measuring range was be-
tween 0.1-20 mg/L.
Plasma uric acid level was measured as a general anti-
oxidant marker at week 12 by a colorimetric kit provided
by Roche Diagnostics (Mannheim, Germany) according
to the instructions of the manufacturer. The detection
limit of the assay was 11.9 μmol/L and the measuring
range was between 11.9-1487 μmol/L.
Statistical analysis
Statistical analysis was performed by using Sigmaplot
12.0 for Windows (Systat Software Inc). All values are
presented as mean ± SEM. Two way ANOVA was used
Table 2 Effect of VMTP preparation on body weight, heart weight and coronary flow (CF)
Parameter Normolipidemia Hyperlipidemia Significance
Placebo VMTP Placebo VMTP
Body weight (g) 472 ± 56 461 ± 25 480 ± 58 480 ± 35 ns
Heart weight (g) 1.59 ± 0.75 1.49 ± 0.55 1.6 ± 0.76 1.66 ± 0.90 ns
(Heart weight/body weight)*1000 3.38 ± 0.12 3.23 ± 0.17 3.33 ± 0.10 3.38 ± 0.15 ns
CF (mL/min) – before ischemia 17.4 ± 1.3 18.9 ± 1.5 19.3 ± 2.6 19.1 ± 2.2 ns
CF (mL/min) – first minute of ischemia 15.7 ± 2.1 20.3 ± 2.3 17.4 ± 4.2 19.9 ± 3.4 ns
CF (mL/min) – during ischemia 19.7 ± 1.2 20.6 ± 1.8 20.5 ± 2.3 25.2 ± 4.0 ns
CF (mL/min) - end of reperfusion 22.0 ± 5.8 16.8 ± 2.0 14.7 ± 2.2 20.3 ± 2.4 ns
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fasting serum cholesterol and triglyceride levels,
plasma hs-CRP and uric acid levels, as well as on the
infarct size. P < 0.05 was accepted as a statistically sig-
nificant difference.
Results
Effect of cholesterol-enriched diet on serum lipid levels
In order to verify the development of hyperlipidemia in
rats fed a 2% cholesterol plus 0.25% cholic acid-enriched
diet, concentrations of fasting serum triglyceride and cho-
lesterol levels were determined at week 0 and 8 (Figure 2).
Baseline serum triglyceride and cholesterol levels did not
differ between groups at week 0. Cholesterol-fed rats
showed a significantly higher serum cholesterol level as
compared to normal rats at week 8 confirming the deve-
lopment of hypercholesterolemia (Figure 2C). However,
serum triglyceride level was not significantly affected by
cholesterol diet at week 8 (Figure 2D).
Effect of VMTP treatment on serum lipid levels, body
weight and heart weight
In order to monitor the effect of VMTP on serum lipid
levels, concentrations of fasting serum triglyceride and
cholesterol were determined after 4 weeks of treatment
(at week 12) in both normo- and hyperlipidemic groups
(Figure 3). In normolipidemic animals, VMTP treatment0
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Figure 4 Effect of the VMTP preparation on infarct size. Area at risk (P
means ± SEM, n = 9-10.did not affect serum triglyceride or cholesterol levels at
week 12 (Figures 3A and 3B). In hyperlipidemic animals,
VMTP treatment significantly decreased serum choles-
terol level as compared to hyperlipidemic placebo-
treated group at week 12 (Figure 3A), however, it did
not change serum triglyceride level (Figure 3B). Body
weight or heart weight was not significantly different
among the experimental groups (Table 2).
Effect of VMTP treatment on area at risk, infarct size and
coronary flow
Infarct size was measured at week 12 to investigate the
severity of ischemia/reperfusion injury and the effect of
VMTP treatment in normolipidemia as well as in hyper-
lipidemia. Neither the presence of hyperlipidemia nor
the VMTP treatment had a significant effect on infarct
size at week 12 (Figure 4). The area-at-risk zone and
coronary flow were not affected significantly in any of
the groups (Figure 4, Table 2).
Effect of VMTP preparation on plasma hs-CRP and uric
acid levels
Plasma hs-CRP level was measured as a systemic en-
dogenous marker of inflammation. Neither the presence
of hyperlipidemia nor the VMTP treatment had a signifi-
cant effect on plasma hs-CRP level at week 12 (Table 3).
Plasma level of uric acid, a well-known antioxidant,B)
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Table 3 Effect of VMTP preparation on plasma hs-CRP and uric acid levels
Parameter Normolipidemia Hyperlipidemia Significance
Placebo VMTP Placebo VMTP
hs-CRP (mg/L) 1.38 ± 0.14 1.19 ± 0.19 1.31 ± 0.12 1.65 ± 0.15 ns
Uric acid (μmol/L) 42.8 ± 12.5 64.8 ± 15.1 75.3 ± 15.3 57.6 ± 11.4 ns
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groups (Table 3).
Discussion
In the present study we have shown that chronic treat-
ment of hyperlipidemic adult male rats with a VMTP
preparation containing 9 vitamins, coenzyme Q10, 5
micro-, and 1 trace element and phytosterol reduces
serum cholesterol, the major risk factor for cardiovascu-
lar disease. However, this preparation failed to affect the
severity of ischemia/reperfusion injury. This is the first
demonstration that although VMTP preparation effec-
tively reduces cholesterol level but does not provide
cardioprotection.
Regular consumption of multivitamins supplemented
with coenzyme Q10 and phytosterols for prevention or
adjunctive treatment of cardiovascular risk factors is
common in developed countries. According to our best
knowledge, there are no preclinical studies available in
the literature investigating the effect of a complex pre-
paration of multivitamins, multiminerals, vitamin-like
substances, and phytosterol on hyperlipidemia. Only one
clinical pilot study evaluated the efficacy and safety of a
similar complex preparation on serum lipid levels [27].
This study involving 25 children and adolescents with
a borderline hypercholesterolemia (serum total choles-
terol 180–240 mg/dL) has shown that a combination
of plant sterol, fish oil and B vitamins significantly reduced
serum total cholesterol, LDL- cholesterol, VLDL-cholesterol,
subfractions LDL-2, IDL-1, IDL-2 and plasma homocysteine
level after 16 weeks of treatment [27]. In our present study,
we have shown that a commercially available VMTP prepa-
ration significantly reduced serum cholesterol level in hyper-
lipidemic but not in normolipidemic rats. However, it did
not affect triglyceride levels in either normolipidemic or
hyperlipidemic animals. These studies show that complex
preparations of multivitamins and phytosterols beneficially
affect the severity of hypercholesterolemia. In our present
study, the VMTP preparation resulted in an approximately
25% reduction in serum cholesterol level in hyperlipidemic
animals. However, clinical trials and their meta-analysis
showed that phytosterol alone may result in an approxi-
mately 4-15% reduction in serum cholesterol level in
hyperlipidemia [35]. Therefore, one may speculate that a
combination of phytosterol with multivitamins, multi-
minerals, and coenzyme Q10 may have an additional
benefit on lipid lowering, possibly via influencingunsaturated fatty acid levels or HMG-CoA activities.
However, this assumption needs further preclinical and
clinical studies.
It is well known that hyperlipidemia is a major risk
factor of myocardial infarction and hyperlipidemia inter-
feres with cardioprotective mechanisms [8]. However,
interestingly there are no data available in the literature
on the cardioprotective effect of any complex multivita-
mins. Therefore, here we investigated the effect of a
VMTP preparation on myocardial infarct size and found
that the VMTP preparation failed to affect infarct size
in normal or cholesterol-fed animals. This is the first
demonstration that a VMTP preparation although effec-
tively reduced serum cholesterol levels it did not provide
cardioprotection.
It should be mentioned that only one experimental
study [36] supports the direct infarct size limiting effect
of a phytosterol derivative in rats. However, there is a
lack of gender distribution in the experimental popula-
tion in this aforementioned study [36]. Taken together,
our present study is the first demonstration that VMTP
preparation effectively reduces cholesterol level but does
not provide cardioprotection. Although the reason for
the lack of cardioprotective effect by VMTP in our study
is not known as no alterations were found in inflamma-
tory markers and antioxidants, it seems that the VMTP
preparation is not able to directly prevent necrosis in an
acute model of myocardial infarction. However, it cannot
be excluded that the VMTP preparation may be able to
confer some cardioprotection in cases when infarct size
is increased.
Our current study is limited in some aspects since it
does not examine the mechanism of the effect of VMTP
preparation and the individual contribution of the 17
different components and their intereactions in the
present model of experimental hyperlipidemia and infarc-
tion. However, it needs to be emphasized that this particu-
lar preparation and others with similar compositions
(multivitamins, vitamin-like substances e.g. coenzyme
Q10, multiminerals, and phytosterols) are commercially
available and regularly consumed by healthy population
and that at risk of cardiovascular disease. Therefore,
thorough investigations of the efficacy and safety of
such products are important in cardiovascular risk.
Future studies investigating the possible preventive ef-
fect of VMTP preparations on the development of
hyperlipidemia are also needed.
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Although VMTP preparations are widely used in
healthy population or by patients with cardiovascular
risk factors including hyperlipidemia, our present study
is the first preclinical demonstration that a VMTP
preparation attenuates the progression of experimental
hypercholesterolemia, however, it does not affect the
severity of ischemia/reperfusion injury in the heart.
Further preclinical and clinical studies are needed to
optimize the compositions and to elucidate the efficacy,
safety and the mechanism of the effect of widely used
VMTP preparations.
Additional file
Additional file 1: Table S1. Ingredients of the Placebo.
Competing interests
Béres Pharmaceuticals Ltd. was the leader of the consortial project funded
by the National Development Agency (MED_FOOD TECH_08-A1-2008-0275).
Author contributions
TC, CK and PF conception and design of research; MS, GS, RG, PB, CS, JB
and IF performed experiments; MS, GS, PB, RG, CS, JB and CC analysed data;
MS, GS, JB, IF and TC interpreted results of experiments; MS prepared figures;
TC, and MS drafted manuscript; MS, TC and PF edited and revised
manuscript; TC, MS, GS, CS, JB, PB, RG, CC, IF, CK and PF approved final
version of manuscript.
Acknowledgments
This work was supported by grants from the National Development Agency
(MED_FOOD TECH_08-A1-2008-0275, Baross DA-TECH-07-2008-0041, TÁMOP-
4.2.1/B-09/1/KONV-2010-0005, TÁMOP-4.2.2/B-10/1-2010-0012, TÁMOP-4.2.2.A-
11/1/KONV-2012-0035), the Hungarian Scientific Research Fund (OTKA
K79167), and co-financed by the European Regional Development Fund and
VÁTI Hungarian Nonprofit LLC for Regional Development and Town Planning
(HURO/0901/137/2.2.2-HU-RO-TRANS-MED). T. Csont held a “János Bolyai
Felowship” of the Hungarian Academy of Sciences. M. Sarkozy and G. Szucs
hold a “Jedlik Ányos Predoctoral Fellowship”. This research was realized in
the frames of TÁMOP 4.2.4. A/2-11-1-2012-0001 National Excellence Program
– Elaborating and operating an inland student and researcher personal
support system. The project was subsidized by the European Union and co-
financed by the European Social Fund. M. Sarkozy holds a “Talent Publication
Support from the University of Szeged, 2012/2013”. We acknowledge the
technical support of Judit Pipis for blood sampling and serum insulin
measurements.
Author details
1Cardiovascular Research Group, Department of Biochemistry, Faculty of
Medicine, University of Szeged, Szeged, Hungary. 2Pharmahungary Group,
Szeged, Hungary. 3Béres Pharmaceuticals Ltd, Budapest, Hungary.
4Department of Laboratory Medicine, Faculty of Medicine, University of
Szeged, Szeged, Hungary. 5Department of Pharmacology and
Pharmacotherapy, Faculty of Medicine, Semmelweis University, Budapest,
Hungary.
Received: 30 July 2013 Accepted: 13 September 2013
Published: 25 September 2013
References
1. Kuklina EV, Yoon PW, Keenan NL: Trends in high levels of low-density
lipoprotein cholesterol in the United States, 1999–2006. JAMA 2009,
302:2104–2110.
2. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB,
Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM,
Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH,Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS,
Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD,
Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB:
American Heart Association Statistics Committee and Stroke Statistics
Subcommittee: Executive summary: heart disease and stroke
statistics–2012 update: a report from the American Heart Association.
Circulation 2012, 125:188–197.
3. Anderson KM, Castelli WP, Levy D: Cholesterol and mortality. 30 years of
follow-up from the Framingham study. JAMA 1987, 257:2176–2180.
4. Rogers WJ, Frederick PD, Stoehr E, Canto JG, Ornato JP, Gibson CM, Pollack
CV Jr, Gore JM, Chandra-Strobos N, Peterson ED, French WJ: Trends in
presenting characteristics and hospital mortality among patients with ST
elevation and non-ST elevation myocardial infarction in the National
Registry of Myocardial Infarction from 1990 to 2006. Am Heart J 2008,
156:1026–1034.
5. Varga ZV, Kupai K, Szucs G, Gaspar R, Paloczi J, Farago N, Zvara A, Puskas LG,
Razga Z, Tiszlavicz L, Bencsik P, Gorbe A, Csonka C, Ferdinandy P, Csont T:
MicroRNA-25-dependent up-regulation of NADPH oxidase 4 (NOX4)
mediates hypercholesterolemia-induced oxidative/nitrative stress and
subsequent dysfunction in the heart. J Mol Cell Cardiol 2013, 62:111–121.
6. Csont T, Bereczki E, Bencsik P, Fodor G, Gorbe A, Zvara A, Csonka C, Puskas
LG, Santha M, Ferdinandy P: Hypercholesterolemia increases myocardial
oxidative and nitrosative stress thereby leading to cardiac dysfunction in
apoB-100 transgenic mice. Cardiovasc Res 2007, 76:100–109.
7. Ferdinandy P, Szilvassy Z, Horvath LI, Csont T, Csonka C, Nagy E,
Szentgyorgyi R, Nagy I, Koltai M, Dux L: Loss of pacing-induced
preconditioning in rat hearts: role of nitric oxide and cholesterol-
enriched diet. J Mol Cell Cardiol 1997, 29:3321–3333.
8. Ferdinandy P, Schulz R, Baxter GF: Interaction of cardiovascular risk factors
with myocardial ischemia/reperfusion injury, preconditioning, and
postconditioning. Pharmacol Rev 2007, 59:418–458.
9. Ungi I, Ungi T, Ruzsa Z, Nagy E, Zimmermann Z, Csont T, Ferdinandy P:
Hypercholesterolemia attenuates the anti-ischemic effect of
preconditioning during coronary angioplasty. Chest 2005, 128:1623–1628.
10. Kupai K, Csonka C, Fekete V, Odendaal L, Van Rooyen J, Marais De W, Csont
T, Ferdinandy P: Cholesterol diet-induced hyperlipidemia impairs the
cardioprotective effect of postconditioning: role of peroxynitrite. Am J
Physiol Heart Circ Physiol 2009, 297:H1729–1735.
11. Schuck RN, Mendys PM, Simpson RJ Jr: Beyond statins: lipid management
to reduce cardiovascular risk. Pharmacotherapy 2013, 33:754–764.
12. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK,
Kaitaniemi P, Koskinen P, Manninen V: Helsinki Heart Study: primary-
prevention trial with gemfibrozil in middle-aged men with dyslipidemia.
Safety of treatment, changes in risk factors, and incidence of coronary
heart disease. N Engl J Med 1987, 317:1237–1245.
13. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ,
Friedewald W: Fifteen year mortality in Coronary Drug Project patients:
long-term benefit with niacin. J Am Coll Cardiol 1986, 8:1245–1255.
14. Li K, Kaaks R, Linseisen J, Rohrmann S: Vitamin/mineral supplementation
and cancer, cardiovascular, and all-cause mortality in a German
prospective cohort (EPIC-Heidelberg). Eur J Nutr 2012, 51:407–413.
15. Bailey RL, Fulgoni VL, Keast DR, Dwyer JT: Examination of vitamin intakes
among US adults by dietary supplement use. J Acad Nutr Diet 2012,
112:657–663.
16. Radimer K, Bindewald B, Hughes J, Ervin B, Swanson C, Picciano MF: Dietary
supplement use by US adults: data from the National Health and Nutrition
Examination Survey, 1999–2000. Am J Epidemiol 2004, 160:339–349.
17. Beitz R, Mensink GB, Fischer B, Thamm M: Vitamins–dietary intake and
intake from dietary supplements in Germany. Eur J Clin Nutr 2002,
56:539–545.
18. Yuvaraj S, Premkumar VG, Vijayasarathy K, Gangadaran SG, Sachdanandam P:
Ameliorating effect of coenzyme Q10, riboflavin and niacin in
tamoxifen-treated postmenopausal breast cancer patients with special
reference to lipids and lipoproteins. Clin Biochem 2007, 40:623–628.
19. Hamoud S, Kaplan M, Meilin E, Hassan A, Torgovicky R, Cohen R, Hayek T:
Niacin administration significantly reduces oxidative stress in patients
with hypercholesterolemia and low levels of high-density lipoprotein
cholesterol. Am J Med Sci 2013, 345:195–199.
20. Lim HJ, Choi YM, Choue R: Dietary intervention with emphasis on folate
intake reduces serum lipids but not plasma homocysteine levels in
hyperlipidemic patients. Nutr Res 2008, 28:767–774.
Csont et al. Lipids in Health and Disease 2013, 12:138 Page 8 of 8
http://www.lipidworld.com/content/12/1/13821. Shidfar F, Homayounfar R, Fereshtehnejad SM, Kalani A: Effect of folate
supplementation on serum homocysteine and plasma total antioxidant
capacity in hypercholesterolemic adults under lovastatin treatment:
a double-blind randomized controlled clinical trial. Arch Med Res 2009,
40:380–386.
22. Dabbagh AJ, Shwaery GT, Keaney JF Jr, Frei B: Effect of iron overload and
iron deficiency on atherosclerosis in the hypercholesterolemic rabbit.
Arterioscler Thromb Vasc Biol 1997, 17:2638–2645.
23. Galhardi CM, Diniz YS, Rodrigues HG, Faine LA, Burneiko RC, Ribas BO,
Novelli EL: Beneficial effects of dietary copper supplementation on serum
lipids and antioxidant defenses in rats. Ann Nutr Metab 2005, 49:283–288.
24. Poirier J, Cockell K, Hidiroglou N, Madere R, Trick K, Kubow S: The effects of
vitamin E and selenium intake on oxidative stress and plasma lipids in
hamsters fed fish oil. Lipids 2002, 37:1125–1133.
25. Talati R, Sobieraj DM, Makanji SS, Phung OJ, Coleman CI: The comparative
efficacy of plant sterols and stanols on serum lipids: a systematic review
and meta-analysis. J Am Diet Assoc 2010, 110:719–726.
26. Laitinen K, Gylling H: Dose-dependent LDL-cholesterol lowering effect by
plant stanol ester consumption: clinical evidence. Lipids Health Dis 2012,
11:140–511. X-11-140.
27. Garaiova I, Muchova J, Nagyova Z, Mislanova C, Oravec S, Dukat A, Wang D,
Plummer SF, Durackova Z: Effect of a plant sterol, fish oil and B vitamin
combination on cardiovascular risk factors in hypercholesterolemic
children and adolescents: a pilot study. Nutr J 2013, 12:7–2891. 12-7.
28. Regulation (EU) No 1169/2011 of the European Parliament and of the
Council of 25 October 2011. Off J Eur Union. http://eur-lex.europa.eu/
LexUriServ/LexUriServ.do?uri=OJ:L:2011:304:0018:0063:EN:PDF.
29. Csont T, Balogh G, Csonka C, Boros I, Horvath I, Vigh L, Ferdinandy P:
Hyperlipidemia induced by high cholesterol diet inhibits heat shock
response in rat hearts. Biochem Biophys Res Commun 2002, 290:1535–1538.
30. Csonka C, Kupai K, Kocsis GF, Novak G, Fekete V, Bencsik P, Csont T,
Ferdinandy P: Measurement of myocardial infarct size in preclinical
studies. J Pharmacol Toxicol Methods 2010, 61:163–170.
31. Kocsis GF, Pipis J, Fekete V, Kovacs-Simon A, Odendaal L, Molnar E, Giricz Z,
Janaky T, van Rooyen J, Csont T, Ferdinandy P: Lovastatin interferes with
the infarct size-limiting effect of ischemic preconditioning and
postconditioning in rat hearts. Am J Physiol Heart Circ Physiol 2008,
294:H2406–2409.
32. Sarkozy M, Zvara A, Gyemant N, Fekete V, Kocsis GF, Pipis J, Szucs G, Csonka
C, Puskas LG, Ferdinandy P, Csont T: Metabolic syndrome influences
cardiac gene expression pattern at the transcript level in male ZDF rats.
Cardiovasc Diabetol 2013, 12(16):12–16.
33. Ferdinandy P, Csonka C, Csont T, Szilvassy Z, Dux L: Rapid pacing-induced
preconditioning is recaptured by farnesol treatment in hearts of
cholesterol-fed rats: role of polyprenyl derivatives and nitric oxide. Mol
Cell Biochem 1998, 186:27–34.
34. Kocsis GF, Sarkozy M, Bencsik P, Pipicz M, Varga ZV, Paloczi J, Csonka C,
Ferdinandy P, Csont T: Preconditioning protects the heart in a prolonged
uremic condition. Am J Physiol Heart Circ Physiol 2012, 303:H1229–1236.
35. Gupta AK, Savopoulos CG, Ahuja J, Hatzitolios AI: Role of phytosterols in
lipid-lowering: current perspectives. QJM 2011, 104:301–308.
36. Zhang S, Li H, Yang SJ: Tribulosin protects rat hearts from ischemia/
reperfusion injury. Acta Pharmacol Sin 2010, 31:671–678.
doi:10.1186/1476-511X-12-138
Cite this article as: Csont et al.: Effect of a multivitamin preparation
supplemented with phytosterol on serum lipids and infarct size in rats fed
with normal and high cholesterol diet. Lipids in Health and Disease
2013 12:138. Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
